Source / episode info

• **Episode:**66
• **Title:**Divine Intervention Episode 66 – Pulmonary Pharmacology For The USMLE
• **Published:**2018-12-17
• Source:Episode page

One-liner

This episode covers the pathophysiology of Type I hypersensitivity reactions, detailing H1 blocker generations and mast cell stabilization; it reviews multiple mechanisms for achieving bronchodilation (Beta-2 agonists, PDE inhibitors); and finally, it details the management strategies for pulmonary hypertension using prostaglandins, phosphodiesterase inhibitors, and endothelin receptor antagonists.

High-yield summary

• Allergy Pathophysiology: The first antibody produced upon initial allergen exposure is IgM. Class switching to IgE requires CD40/CD40L interaction. Mast cell degranulation occurs via cross-linking of IgE bound to the FcεRI receptor, releasing histamine and bradykinin.
• Anti-histamines: First-generation H1 blockers (e.g., diphenhydramine) are highly sedating due to potent muscarinic antagonism and can cross the blood-brain barrier; second-generation agents (e.g., loratadine) do not.
• Bronchodilation Mechanisms: Bronchoconstriction can be reversed by: 1) activating _2 receptors ( cAMP); 2) blocking muscarinic receptors (anticholinergics); or 3) inhibiting leukotriene synthesis/action (e.g., Montelukast).
• Aspirin-Exacerbated Respiratory Disease (AERD): This condition results from irreversible COX inhibition (e.g., aspirin), which shunts arachidonic acid metabolism toward the LOX pathway, causing excessive and problematic leukotriene production.
• Pulmonary Hypertension (PAH): Treatment targets include: 1) Prostaglandin analogs (Epoprostenol); 2) PDE5 inhibitors (Sildenafil/Tadalafil); or 3) Endothelin receptor antagonists (Bosentan).

Learning objectives

• Describe the immunological cascade leading to Type I hypersensitivity reactions, identifying the role of IgE and mast cell mediators.
• Differentiate between the mechanisms of action for various bronchodilator classes (e.g., \beta_2 agonists vs. anticholinergics).
• Explain the pathophysiology of leukotriene overproduction in AERD following COX inhibition.
• Identify appropriate pharmacological agents and targets for managing pulmonary arterial hypertension based on underlying mechanism.
• Recognize the clinical implications of first-generation versus second-generation anti-histamines regarding CNS penetration and side effects.

Board exam buzzwords